Calquence and Inrebic

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.MONITOR CLOSELY: Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Serious and fatal hemorrhagic events have been reported during acalabrutinib therapy. In the combined safety database of 612 patients with hematologic malignancies treated with acalabrutinib monotherapy, grade 3 or higher bleeding events including gastrointestinal, intracranial, and epistaxis occurred in 2% of patients. Overall, bleeding events of any grade occurred in approximately 50% of patients. The mechanism for the bleeding events is not well understood, although treatment with acalabrutinib commonly causes thrombocytopenia. Treatment-emergent grade 3 or 4 thrombocytopenia was reported in 8% of patients in the combined safety database, while thrombocytopenia of all grades was reported in greater than 40% of patients. MANAGEMENT: Concomitant use of acalabrutinib in patients receiving other medications that interfere with platelet function or coagulation should be approached with caution. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The INR should be monitored more frequently during coadministration of warfarin or other vitamin K antagonists. Patients should be advised to promptly report any signs of bleeding to their physician. References "Product Information. Calquence (acalabrutinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.

MONITOR CLOSELY: Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Serious and fatal hemorrhagic events have been reported during acalabrutinib therapy. In the combined safety database of 612 patients with hematologic malignancies treated with acalabrutinib monotherapy, grade 3 or higher bleeding events including gastrointestinal, intracranial, and epistaxis occurred in 2% of patients. Overall, bleeding events of any grade occurred in approximately 50% of patients. The mechanism for the bleeding events is not well understood, although treatment with acalabrutinib commonly causes thrombocytopenia. Treatment-emergent grade 3 or 4 thrombocytopenia was reported in 8% of patients in the combined safety database, while thrombocytopenia of all grades was reported in greater than 40% of patients.

MANAGEMENT: Concomitant use of acalabrutinib in patients receiving other medications that interfere with platelet function or coagulation should be approached with caution. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The INR should be monitored more frequently during coadministration of warfarin or other vitamin K antagonists. Patients should be advised to promptly report any signs of bleeding to their physician.

Calquence

Generic Name: acalabrutinib

Brand name: Calquence

Synonyms: n.a.

What is Calquence?

Inrebic

Generic Name: fedratinib

Brand name: Inrebic

Synonyms: n.a.

What is Inrebic?